Methods for identifying erbb2 alteration in tumors
AssigneesIpsogen, Inserm (Institut National De La Sante Et De La Recherche Medicale), Institut Paoli-Calmettes
InventorsFrancois Bertucci, Rebecca Tagett, Sabrina Carpentier
Life of this patent
Estimating the term…
Abstract
Methods for identifying ERBB2 (also named HER2) alteration in tumors, in particular cancer, based on the analysis of the expression of at least three genes of the ERBB2 amplicon located within less than one megabase on either side of ERBB2, and eventually of the gene corresponding to the Affymetrix probeset 234046_at (SEQ ID NO: 31), as well as a poynucleotide library useful for the molecular characterization of a cancer including polynucleotide sequences for detecting the genes, and a kit including the library.
Claims37
A method for identifying ERBB2 alteration in tumors, in particular cancer, based on the analysis of the over or under expression of genes in a tissue sample, said analysis comprising :
- the detection of the expression of a group of genes comprising, or consisting of:
- at least three, or at least four, or at least five, or at least six, or at least seven, or of eight genes of the ERBB2 amplicon, these genes being located within less than one megabase on either side of ERBB2, or
- the detection of the expression of a group of genes comprising, or consisting of:
- at least three, or at least four, or at least five, or at least six, or at least seven, or of eight genes of the ERBB2 amplicon, these genes being located within less than one megabase on either side of ERBB2, and the gene corresponding to SEQ ID NO. 31.
A method for determining amplification of ERBB2 gene locus on chromosome 17q12-17q21.1 comprising determining the expression level of one or more RNA transcripts or their expression products in a biological sample containing cancer cells obtained from said subject, wherein the RNA transcript is of at least one, at two, at least three, or at least four, or at least five, or at least six, or at least seven, or of eight or larger group of genes selected from the group of genes located within less than one megabase on either side of ERBB2 gene on chromosome 17q12-17q21.1.
A method for predicting the response of a subject diagnosed with ERBB2 positive cancer to treatment with an ERBB2 inhibitor, comprising determining the expression level of one or more RNA transcripts or their expression products in a biological sample containing cancer cells obtained from said subject, wherein the RNA transcript is of one or more genes selected from the group consisting of ERBB2 and genes located near ERBB2 on chromosome 17q12-17q21.1
Dependencies are inferred from the claim text.